40 articles
Narlumosbart
Narlumosbart (JMT103, Jinlitai, 津立泰) is a fully human IgG4 anti-RANKL monoclonal antibody by Shanghai JMT-Bio/CSPC, conditionally approved in China in 2023 for unresectable giant cell tumor of bone, with 93.5% tumor response rate.
Pegilodecakin
Pegilodecakin, known by the development codes AM0010 and LY3500518, is a PEGylated interleukin-10 drug investigated as a cancer immunotherapy that reached phase 3 testing but was never approved.
Pembrolizumab plus pemetrexed regimen
The pembrolizumab plus pemetrexed regimen, also called pembrolizumab-pemetrexed, is a first-line chemoimmunotherapy combining pembrolizumab, pemetrexed, and a platinum drug, approved in 2018 for metastatic nonsquamous non-small-cell lung cancer.
Pertuzumab/trastuzumab regimen
The pertuzumab/trastuzumab regimen is a dual HER2-targeted antibody combination, usually given with chemotherapy or endocrine therapy, used to treat HER2-positive breast cancer in metastatic, neoadjuvant, and adjuvant settings, first FDA-approved in 2012.
Polatuzumab vedotin and rituximab regimen
The polatuzumab vedotin and rituximab regimen (Pola-R) is a chemoimmunotherapy pairing for B-cell lymphomas, approved with R-CHP for untreated diffuse large B-cell lymphoma and with bendamustine for relapsed disease.
Tertomotide
Tertomotide (GV1001, Riavax) is a 16-amino-acid telomerase (hTERT 611-626) peptide cancer vaccine from GemVax & KAEL; immunogenic in pancreatic, lung cancer and melanoma trials, but it failed to improve survival in the TeloVac phase III pancreatic trial and is now studied for Alzheimer's disease.
Tesevatinib
Tesevatinib (XL647, KD019, EXEL-7647) is an oral multikinase inhibitor of EGFR, HER2, VEGFR, EphB4, and Src, trialed in EGFR-mutant NSCLC with brain metastases, glioblastoma, and polycystic kidney disease; never approved, its ADPKD phase 2 trial failed.
Tilsotolimod
Tilsotolimod (IMO-2125) is a synthetic Toll-like receptor 9 agonist oligonucleotide developed by Idera Pharmaceuticals for intratumoral injection with checkpoint inhibitors in anti-PD-1 refractory melanoma; the phase 3 ILLUMINATE-301 trial failed, and development was discontinued in December 2021.
Trastuzumab regimen
A trastuzumab regimen is a cancer treatment pairing trastuzumab, a monoclonal antibody against the HER2 receptor, with chemotherapy, used mainly in HER2-positive breast and gastric cancers.
Velimogene aliplasmid
Velimogene aliplasmid (Allovectin-7, VCL-1005) was Vical's intralesional plasmid-lipid gene therapy encoding HLA-B7 and beta-2 microglobulin for melanoma; phase 3 trials failed and the program was terminated in 2013.